Hinge Health, Inc. provides a technology platform for digital health care, with a core focus on musculoskeletal conditions. The company combines an AI-powered care model, wearable devices, motion-tracking technology and access to clinicians to deliver personalized, evidence-based care for members and cost-management programs for employer, public-sector and health-plan clients.
News about Hinge Health commonly covers quarterly results and guidance, client expansion, outcomes research for chronic pain programs, and product development. Recurring updates also include the FDA-cleared Enso wearable device, the company’s Migraine Care Program, public-sector adoption of its MSK care platform, board and governance changes, and capital actions tied to its Class A common stock.
Hinge Health (NYSE: HNGE) reported record Q1 2026 results: revenue $182.3M (+47% YoY) and GAAP gross margin 85%. Management raised full‑year revenue guidance by about $64M to a midpoint of $801M and expects a 26% non‑GAAP operating margin for 2026. Cash and equivalents totaled $407.1M. Q2 revenue guidance is $194M–$196M; full‑year revenue guidance is $798M–$804M. The company did not provide a reconciliation of non‑GAAP operating guidance to GAAP due to variability in stock‑based compensation and related items.
Hinge Health (NYSE: HNGE) launched a Migraine Care Program, combining its FDA-cleared Enso® wearable for rapid, drug-free migraine relief with AI-powered trigger tracking, exercise therapy, and expert-led prevention. More than 125 clients covering 2+ million people have adopted the program. Rollout begins May 2026.
Hinge Health (NYSE: HNGE) will report first-quarter 2026 financial results for the quarter ended March 31, 2026, after U.S. markets close on May 5, 2026. The company will host an earnings conference call at 1:30 p.m. PT / 4:30 p.m. ET that day, with a live audio webcast and replay available on its investor relations website.
Hinge Health (NYSE: HNGE) expanded its public sector reach, now serving 24 state employee health plan clients and supporting over 300 public sector organizations. The program delivers 24/7 musculoskeletal (MSK) care across all 50 states and reaches more than 5 million people in state and local governments, higher education, and public institutions.
The care model emphasizes early intervention, accessibility, and evidence-based digital programs designed for diverse public-sector roles and schedules.
Hinge Health (NYSE: HNGE) appointed Tyler Sloat to its board of directors effective March 17, 2026. Sloat is currently CFO and COO of Freshworks and has nearly three decades of operational leadership across technology companies.
He previously served as CFO at Zuora, guiding the company through its 2018 IPO, and has held senior roles at NetApp and Siebel. Hinge Health said Sloat’s experience in scaling public companies and financial discipline will support its mission to automate healthcare delivery and improve member outcomes while reducing client costs.
Hinge Health (NYSE: HNGE) reported record Q4 and full‑year 2025 results, with revenue up 46% in Q4 to $170.7M and 51% for the year to $587.9M. Non‑GAAP operating income turned positive to $119.5M for 2025 and the company generated $179.6M in free cash flow. The board authorized a $250M share repurchase program and repurchased $65M in Q4. Management provided 2026 guidance: Q1 revenue $171M–$173M and FY2026 revenue $732M–$742M, with non‑GAAP operating margin expansion expected to ~21% by year end.
Hinge Health (NYSE: HNGE) will report fourth quarter and full year 2025 financial results after U.S. markets close on Tuesday, February 10, 2026.
The company will host an earnings conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and a replay will be available on the Hinge Health investor relations website at ir.hingehealth.com.
Hinge Health (NYSE: HNGE) published a peer-reviewed study reporting that participants in its chronic back pain program had 60% fewer imaging visits (X-rays and MRIs) at three months versus a matched group receiving traditional physical therapy. The study analyzed 4,330 participants enrolled Jan–Oct 2020 using claims from a U.S. commercial database covering > 100 million commercially insured lives from Jan 1, 2016–Sep 30, 2021.
The authors note imaging is often not clinically indicated and can trigger unnecessary tests, specialist visits, procedures, and costs; the study complements prior claims-based findings of reductions in surgeries and opioid prescriptions associated with Hinge Health care.
Hinge Health (NYSE: HNGE) announced a $250 million share repurchase program approved by its board on November 10, 2025. The company reported $108 million cash from operations and $118 million free cash flow in the first nine months of 2025, and held nearly $500 million in cash and investments at end of Q3 2025.
Repurchases may occur in the open market, via privately negotiated transactions, or under Rule 10b5-1 plans; timing and amounts are at the company’s discretion. The program may be funded from existing cash and ongoing operations and does not obligate any specific purchases.
Summary not available.